Loading patent…
AssigneeOnconova Therapeutics, Inc.
InventorsStanley C. Bell, Manoj Maniar
Estimating the term…
Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of a compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.
An aqueous composition for parenteral administration comprising an effective amount of a sodium salt of (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone (ON 01910.Na) and 25% to 47.5% by weight of a polyethylene glycol comprising PEG 300, PEG 400, PEG 600, or PEG 800, and a buffer, wherein the composition is in a pH range of about 8 to about 14, and wherein the buffer is a phosphate buffer and osmolarity of the aqueous composition is 300 mOsm/kg.
A composition for prevention or treatment of a pathophysiological condition in a mammal consisting essentially of about 4% to about 10% by weight of sodium salt of (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzylsulfone (ON 01910.Na) and 25% to 47.5% by weight of a polyethylene glycol comprising PEG 300, PEG 400, PEG 600, or PEG 800, and a buffer, wherein the composition is in a pH range of about 8 to about 14, and wherein the buffer is a phosphate buffer and osmolarity of the aqueous composition is 300 mOsm/kg.
Dependencies are inferred from the claim text.